Description: Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Home Page: turnstonebio.com
9310 Athena Circle
La Jolla,
CA
92037
United States
Phone:
347 897 5988
Officers
| Name | Title |
|---|---|
| Dr. Sammy J. Farah M.B.A., Ph.D. | President, CEO & Director |
| Dr. Michael F. Burgess M.D., MBChB, Ph.D. | Executive Director |
| Ms. Wendy Worcester CFA, CPA | VP, Principal Finance & Accounting Officer |
| Ms. Saryah Azmat | Chief Operating Officer |
| Dr. David Stojdl Ph.D. | Senior Vice President of Research & Discovery |
| Dr. Ines Verdon M.D. | Senior Vice President of Clinical Development |
| Dr. Michael Fitch Ph.D. | Senior Vice President of Manufacturing |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2554 |
| Price-to-Sales TTM: | 2.1344 |
| IPO Date: | 2023-07-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 80 |